News

BEAT Stock Earnings: HeartBeam Meets EPS for Q4 2023

  • HeartBeam (NASDAQ: BEAT ) just reported results for the fourth quarter of 2023. HeartBeam reported earnings per share of -13 cents.
    03/20/2024

HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript

  • HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript
    03/20/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

HeartBeam, Inc. (BEAT) can sell. Click on Rating Page for detail.

The price of HeartBeam, Inc. (BEAT) is 2.1705 and it was updated on 2024-03-28 13:00:39.

Currently HeartBeam, Inc. (BEAT) is in undervalued.

News
    
News

HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time

  • SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Fourth Quarter and Full Year 2023 Results Conference Call on Wednesday March 20, 2024 at 4:30 p.m. Eastern Time.
    Tue, Mar. 05, 2024

HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time

  • SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Third Quarter 2023 Results Conference Call on Tuesday November 14, 2023 at 4:30 p.m. Eastern Time.
    Tue, Oct. 31, 2023

HeartBeam, Inc. (BEAT) Q2 2023 Earnings Call Transcript

  • HeartBeam, Inc. (NASDAQ:BEAT ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder & Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
    Sun, Aug. 13, 2023

HeartBeam, Inc. (BEAT) Q1 2023 Earnings Call Transcript

  • HeartBeam, Inc. (NASDAQ:BEAT ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Rob Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James William Sutherland - The Benchmark Company Ben Haynor - Alliance Global Partners Operator Greetings and welcome to the HeartBeam First Quarter 2023 Financial Results Conference Call. At this time all participants are in listen only mode.
    Sun, May. 14, 2023

6 Disruptive Stocks That Will Benefit From Interest Rate Policy Change

  • Early commercial stage companies burn cash as they scale. A rising interest rate environment is a headwind for companies burning cash.
    Thu, Apr. 13, 2023
SEC Filings
SEC Filings

HeartBeam, Inc. (BEAT) - SC 13D

  • SEC Filings
  • 10/25/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 10/03/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 09/29/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 09/27/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 09/22/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 09/19/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 09/15/2023

HeartBeam, Inc. (BEAT) - SC 13D

  • SEC Filings
  • 08/28/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 08/04/2023

HeartBeam, Inc. (BEAT) - 3

  • SEC Filings
  • 08/02/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 07/18/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 07/17/2023

HeartBeam, Inc. (BEAT) - S-8

  • SEC Filings
  • 07/13/2023

HeartBeam, Inc. (BEAT) - 3

  • SEC Filings
  • 06/15/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 06/09/2023

HeartBeam, Inc. (BEAT) - SC 13D

  • SEC Filings
  • 06/02/2023

HeartBeam, Inc. (BEAT) - DEF 14A

  • SEC Filings
  • 05/26/2023

HeartBeam, Inc. (BEAT) - PRE 14A

  • SEC Filings
  • 05/16/2023

HeartBeam, Inc. (BEAT) - 3

  • SEC Filings
  • 05/15/2023

HeartBeam, Inc. (BEAT) - 424B2

  • SEC Filings
  • 05/04/2023

HeartBeam, Inc. (BEAT) - EFFECT

  • SEC Filings
  • 04/21/2023

HeartBeam, Inc. (BEAT) - 424B2

  • SEC Filings
  • 04/21/2023

HeartBeam, Inc. (BEAT) - S-1/A

  • SEC Filings
  • 04/17/2023

HeartBeam, Inc. (BEAT) - S-1/A

  • SEC Filings
  • 04/10/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 03/23/2023

HeartBeam, Inc. (BEAT) - 424B2

  • SEC Filings
  • 03/09/2023

HeartBeam, Inc. (BEAT) - DEL AM

  • SEC Filings
  • 02/28/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 02/14/2023

HeartBeam, Inc. (BEAT) - EFFECT

  • SEC Filings
  • 02/13/2023

HeartBeam, Inc. (BEAT) - SC 13G/A

  • SEC Filings
  • 02/13/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 02/13/2023

HeartBeam, Inc. (BEAT) - S-1

  • SEC Filings
  • 02/10/2023

HeartBeam, Inc. (BEAT) - S-3

  • SEC Filings
  • 02/02/2023

HeartBeam, Inc. (BEAT) - 3

  • SEC Filings
  • 01/27/2023

HeartBeam, Inc. (BEAT) - SC 13G/A

  • SEC Filings
  • 01/10/2023

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 12/02/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 11/02/2022

HeartBeam, Inc. (BEAT) - 3/A

  • SEC Filings
  • 10/14/2022

HeartBeam, Inc. (BEAT) - DEF 14A

  • SEC Filings
  • 10/11/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 10/07/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 10/03/2022

HeartBeam, Inc. (BEAT) - PRE 14A

  • SEC Filings
  • 09/28/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 09/02/2022

HeartBeam, Inc. (BEAT) - 3

  • SEC Filings
  • 08/12/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 08/02/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 07/19/2022

HeartBeam, Inc. (BEAT) - S-8

  • SEC Filings
  • 07/13/2022

HeartBeam, Inc. (BEAT) - 4/A

  • SEC Filings
  • 07/06/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 07/06/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 06/21/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 06/17/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 06/02/2022

HeartBeam, Inc. (BEAT) - DEF 14A

  • SEC Filings
  • 05/02/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 05/02/2022

HeartBeam, Inc. (BEAT) - PRE 14A

  • SEC Filings
  • 04/22/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 04/04/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 03/31/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 03/03/2022

HeartBeam, Inc. (BEAT) - SC 13G/A

  • SEC Filings
  • 02/03/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 02/03/2022

HeartBeam, Inc. (BEAT) - 4/A

  • SEC Filings
  • 01/06/2022

HeartBeam, Inc. (BEAT) - SC 13G/A

  • SEC Filings
  • 01/05/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 01/03/2022

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 12/23/2021

HeartBeam, Inc. (BEAT) - 3

  • SEC Filings
  • 12/23/2021

HeartBeam, Inc. (BEAT) - S-8

  • SEC Filings
  • 12/01/2021

HeartBeam, Inc. (BEAT) - S-8

  • SEC Filings
  • 11/30/2021

HeartBeam, Inc. (BEAT) - 424B1

  • SEC Filings
  • 11/18/2021

HeartBeam, Inc. (BEAT) - SC 13G

  • SEC Filings
  • 11/17/2021

HeartBeam, Inc. (BEAT) - 424B1

  • SEC Filings
  • 11/17/2021

HeartBeam, Inc. (BEAT) - SC 13G

  • SEC Filings
  • 11/16/2021

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 11/16/2021

HeartBeam, Inc. (BEAT) - 4

  • SEC Filings
  • 11/15/2021

HeartBeam, Inc. (BEAT) - EFFECT

  • SEC Filings
  • 11/12/2021

HeartBeam, Inc. (BEAT) - EFFECT

  • SEC Filings
  • 11/12/2021

HeartBeam, Inc. (BEAT) - CERT

  • SEC Filings
  • 11/12/2021

HeartBeam, Inc. (BEAT) - 424B1

  • SEC Filings
  • 11/12/2021

HeartBeam, Inc. (BEAT) - 3

  • SEC Filings
  • 11/12/2021

HeartBeam, Inc. (BEAT) - 8-A12B

  • SEC Filings
  • 11/10/2021

HeartBeam, Inc. (BEAT) - S-1/A

  • SEC Filings
  • 11/09/2021

HeartBeam, Inc. (BEAT) - S-1/A

  • SEC Filings
  • 11/08/2021

HeartBeam, Inc. (BEAT) - CORRESP

  • SEC Filings
  • 11/08/2021

HeartBeam, Inc. (BEAT) - S-1/A

  • SEC Filings
  • 11/02/2021

HeartBeam, Inc. (BEAT) - S-1/A

  • SEC Filings
  • 11/01/2021

HeartBeam, Inc. (BEAT) - FWP

  • SEC Filings
  • 11/01/2021

HeartBeam, Inc. (BEAT) - CORRESP

  • SEC Filings
  • 10/19/2021

HeartBeam, Inc. (BEAT) - S-1/A

  • SEC Filings
  • 10/12/2021

HeartBeam, Inc. (BEAT) - CORRESP

  • SEC Filings
  • 10/12/2021

HeartBeam, Inc. (BEAT) - UPLOAD

  • SEC Filings
  • 10/07/2021

HeartBeam, Inc. (BEAT) - S-1/A

  • SEC Filings
  • 10/04/2021

HeartBeam, Inc. (BEAT) - CORRESP

  • SEC Filings
  • 10/04/2021

HeartBeam, Inc. (BEAT) - UPLOAD

  • SEC Filings
  • 09/14/2021

HeartBeam, Inc. (BEAT) - S-1

  • SEC Filings
  • 09/07/2021

HeartBeam, Inc. (BEAT) - CORRESP

  • SEC Filings
  • 09/07/2021

HeartBeam, Inc. (BEAT) - UPLOAD

  • SEC Filings
  • 07/21/2021

HeartBeam, Inc. (BEAT) - DRSLTR

  • SEC Filings
  • 07/09/2021

HeartBeam, Inc. (BEAT) - DRS/A

  • SEC Filings
  • 07/09/2021

HeartBeam, Inc. (BEAT) - UPLOAD

  • SEC Filings
  • 06/11/2021

HeartBeam, Inc. (BEAT) - DRS

  • SEC Filings
  • 05/14/2021

HeartBeam, Inc. (BEAT) - SC 13G/A

  • SEC Filings
  • 03/10/2021

HeartBeam, Inc. (BEAT) - 15-12G

  • SEC Filings
  • 02/19/2021

HeartBeam, Inc. (BEAT) - SC 13G/A

  • SEC Filings
  • 02/16/2021

HeartBeam, Inc. (BEAT) - SC TO-T/A

  • SEC Filings
  • 02/09/2021

HeartBeam, Inc. (BEAT) - S-8 POS

  • SEC Filings
  • 02/09/2021

HeartBeam, Inc. (BEAT) - POSASR

  • SEC Filings
  • 02/09/2021

HeartBeam, Inc. (BEAT) - 25-NSE

  • SEC Filings
  • 02/09/2021

HeartBeam, Inc. (BEAT) - SC 14D9/A

  • SEC Filings
  • 02/04/2021

HeartBeam, Inc. (BEAT) - SC TO-T/A

  • SEC Filings
  • 02/01/2021

HeartBeam, Inc. (BEAT) - SC 14D9/A

  • SEC Filings
  • 01/29/2021

HeartBeam, Inc. (BEAT) - SC 14D9/A

  • SEC Filings
  • 01/26/2021

HeartBeam, Inc. (BEAT) - SC 13G

  • SEC Filings
  • 01/25/2021

HeartBeam, Inc. (BEAT) - SC TO-T/A

  • SEC Filings
  • 01/20/2021

HeartBeam, Inc. (BEAT) - SC 14D9/A

  • SEC Filings
  • 01/20/2021

HeartBeam, Inc. (BEAT) - SC 14D9/A

  • SEC Filings
  • 01/07/2021

HeartBeam, Inc. (BEAT) - SC TO-T/A

  • SEC Filings
  • 01/04/2021

HeartBeam, Inc. (BEAT) - SC TO-T

  • SEC Filings
  • 12/23/2020

HeartBeam, Inc. (BEAT) - SC 14D9

  • SEC Filings
  • 12/23/2020

HeartBeam, Inc. (BEAT) - SC14D9C

  • SEC Filings
  • 12/22/2020

HeartBeam, Inc. (BEAT) - SC TO-C

  • SEC Filings
  • 12/22/2020

HeartBeam, Inc. (BEAT) - SC14D9C

  • SEC Filings
  • 12/21/2020

HeartBeam, Inc. (BEAT) - SC TO-C

  • SEC Filings
  • 12/21/2020

HeartBeam, Inc. (BEAT) - SC14D9C

  • SEC Filings
  • 12/18/2020

HeartBeam, Inc. (BEAT) - SD

  • SEC Filings
  • 05/28/2020

HeartBeam, Inc. (BEAT) - S-3ASR

  • SEC Filings
  • 05/08/2020

HeartBeam, Inc. (BEAT) - DEFA14A

  • SEC Filings
  • 04/27/2020

HeartBeam, Inc. (BEAT) - DEFA14A

  • SEC Filings
  • 03/24/2020

HeartBeam, Inc. (BEAT) - DEF 14A

  • SEC Filings
  • 03/24/2020

HeartBeam, Inc. (BEAT) - 5

  • SEC Filings
  • 02/14/2020

HeartBeam, Inc. (BEAT) - SC 13G/A

  • SEC Filings
  • 02/12/2020

HeartBeam, Inc. (BEAT) - SC 13G/A

  • SEC Filings
  • 02/04/2020

HeartBeam, Inc. (BEAT) - SC 13G

  • SEC Filings
  • 01/10/2020

HeartBeam, Inc. (BEAT) - D

  • SEC Filings
  • 08/16/2019

HeartBeam, Inc. (BEAT) - SD

  • SEC Filings
  • 05/31/2019
Press Releases
StockPrice Release
More Headlines
News

HeartBeam, Inc. (BEAT) Q4 2022 Earnings Call Transcript

  • HeartBeam, Inc. (NASDAQ:BEAT ) Q4 2022 Results Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Branislav Vajdic - Founder and Chief Executive Officer Robert Eno - President Richard Brounstein - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James William Sutherland - The Benchmark Company Ben Haynor - Alliance Global Partners Operator Greetings. And welcome to the HeartBeam Fourth Quarter and Full-Year 2022 Financial Results Conference Call.
  • 03/17/2023

Cash Out Or Hold On To HeartBeam?

  • I can only give HeartBeam a hold rating. This cardiac technology firm's stock has risen too much recently. BEAT's 3-month price performance is +349.22%. I think investors should take profit now because its product still has no FDA approval. Zero revenue until now.
  • 12/16/2022

HeartBeam, Inc. (BEAT) Q3 2022 Earnings Call Transcript

  • HeartBeam, Inc. (NASDAQ:BEAT ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Branislav Vajdic – Founder and Chief Executive Officer Jon Hunt – Chief Business Officer Rick Brounstein – Chief Financial Officer Conference Call Participants Jason Kolbert – Dawson James Bill Sutherland – The Benchmark Company Operator Greetings, and welcome to the HeartBeam Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
  • 11/12/2022

HeartBeam to Host Third Quarter 2022 Results Conference Call on Thursday November 10, 2022 at 4:30 p.m. Eastern Time

  • SANTA CLARA, Calif.
  • 10/25/2022

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

  • The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
  • 10/24/2022

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

  • September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
  • 10/17/2022

HeartBeam to Present at LD Micro Main Event XV Conference

  • SANTA CLARA, Calif.
  • 10/13/2022

Why Is HeartBeam (BEAT) Stock Up 24% Today?

  • Source: shutterstock.com/Anastasia Zagoruyko HeartBeam (NASDAQ: BEAT ) stock is seeing gains on Thursday as investors react to news of it expanding its product portfolio pipeline. That expansion has the company working to develop arrhythmia detection capabilities.
  • 10/06/2022

HeartBeam to Present at Upcoming Investor Conferences

  • SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Present at Upcoming Investor Conferences
  • 09/29/2022

Penny Stocks To Buy Now: 3 To Watch Under $3

  • Penny stocks to buy for under $3 The post Penny Stocks To Buy Now: 3 To Watch Under $3 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/22/2022

Buying Penny Stocks Today? What You Need to Know

  • Here's what you need to know about trading penny stocks on September 16th The post Buying Penny Stocks Today? What You Need to Know  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 09/16/2022

HeartBeam stock jumps amid heart monitor device patent

  • Yahoo Finance Live looks at cardiac technology company HeartBeam's stock after receiving a patent for a device in detecting heartbeat irregularities.
  • 09/15/2022

What Is Going on With HeartBeam (BEAT) Stock Today?

  • Source: shutterstock.com/Anastasia Zagoruyko HeartBeam (NASDAQ: BEAT ) stock is rocketing higher on Thursday as investors react to news of a new heart monitor patent. This new patent covers a 12-lead electrocardiogram patch that's designed to monitor for acute coronary syndrome, as well as cardiac arrhythmia.
  • 09/15/2022

HeartBeam, Inc. (BEAT) CEO Branislav Vajdic on Q2 2022 Results - Earnings Call Transcript

  • HeartBeam, Inc. (NASDAQ:BEAT ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Branislav Vajdic - Chief Executive Officer & Founder Jon Hunt - Chief Business Officer Rick Brounstein - Chief Financial Officer Conference Call Participants Bill Sutherland - The Benchmark Company Jason Kolbert - Dawson James Operator Greetings and welcome to the HeartBeam Second Quarter 2022 Financial Results Conference Call. At this time, all participants will be in a listen-only mode.
  • 08/12/2022

HeartBeam to Host Second Quarter 2022 Results Conference Call on Thursday August 11, 2022 at 4:30 p.m. Eastern Time

  • SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2022 Results Conference Call on Thursday August 11, 2022 at 4:30 p.m. Eastern Time
  • 07/26/2022

HeartBeam to Present at LD Micro Invitational XII Conference on June 7, 2022

  • SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Present at LD Micro Invitational XII Conference on June 7, 2022
  • 05/25/2022

HeartBeam to Participate in the H.C. Wainwright Global Investment Conference May 23-26, 2022

  • SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Participate in the H.C. Wainwright Global Investment Conference May 23-26, 2022
  • 05/18/2022

HeartBeam to Host First Quarter 2022 Results Conference Call on Thursday May 12, 2022 at 4:30 p.m. Eastern Time

  • SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host First Quarter 2022 Results Conference Call on Thursday May 12, 2022 at 4:30 p.m. Eastern Time
  • 04/28/2022

HeartBeam to Host Fourth Quarter and Full Year 2021 Results Conference Call on Thursday, March 24, 2022 at 4:30 p.m. Eastern Time

  • SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Fourth Quarter and Full Year 2021 Results Conference Call on Thursday, March 24, 2022 at 4:30 p.m. Eastern Time
  • 03/07/2022

Making a List of Penny Stocks to Buy? Check These 3 Out Right Now

  • Check these penny stocks out for your watchlist right now The post Making a List of Penny Stocks to Buy? Check These 3 Out Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
  • 12/20/2021

HeartBeam: Cardiovascular Diagnostics On The Go

  • HeartBeam is pioneering a breakthrough ECG telemedicine solution. A credit card size device sends ECG recording to a cloud software enabling CVD diagnosis in ambulatory settings outside of a hospital.
  • 12/14/2021

HeartBeam IPO: Why BEAT Stock Has Investors' Hearts Racing Friday

  • A heart health innovator went public yesterday. Here's why you shouldn't be worried by the turbulence of the HeartBeam IPO.
  • 11/12/2021

Philips (PHG) Expands Portfolio With BioTelemetry Acquisition

  • Philips (PHG) enters into a deal to acquire BioTelemetry, which drives the expansion of its cardiac care portfolio and fuels customer acquisition.
  • 12/21/2020

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - BEAT, SNCA, BBIO, TLRY, NEOS

  • NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: BioTelemetry, Inc. (NASDAQ: BEAT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating...
  • 12/19/2020

SHAREHOLDER ALERT: WeissLaw LLP Investigates BioTelemetry, Inc.

  • NEW YORK, Dec. 18, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioTelemetry, Inc. ("BioTelemetry" or the "Company") (NASDAQ: BEAT) in connection with the proposed acquisition of the Company...
  • 12/18/2020

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of BioTelemetry, Inc. - BEAT

  • NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating BioTelemetry, Inc. ("BEAT" or the "Company") (BEAT) relating to its...
  • 12/18/2020

BIOTELEMETRY ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of BEAT and Encourages Investors to Contact the Firm

  • NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Koninklijke Philips N.V. (NYSE: PHG) (“Royal Philips”).
  • 12/18/2020

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of BioTelemetry, Inc.

  • NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by BioTelemetry, Inc. (NASDAQ: BEAT) and its board of directors concerning the proposed acquisition of the company by Royal Philips (NYSE: PHG). Stockholders will receive $72.00...
  • 12/18/2020

BioTelemetry soars 18% after Philips announces acquisition of cardiac-diagnostics company

  • BioTelemetry gained as much as 18% on Friday after news that the cardiac-diagnostics firm will be acquired by Dutch company Royal Philips for $2.8 billion. BioTelemetry is a Pennsylvania-based medical company that makes equipment that remotely diagnoses and monitors cardiac activity.
  • 12/18/2020

BioTelemetry Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of BioTelemetry, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – BEAT

  • NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioTelemetry, Inc. (NASDAQ: BEAT) to Royal Philips for $72.00 per share in cash is fair to BioTelemetry shareholders. Halper Sadeh encourages BioTelemetry shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether B
  • 12/18/2020

(BEAT) Alert: Johnson Fistel Investigates Proposed Sale of BioTelemetry; Is $72 a Fair Price?

  • SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of BioTelemetry, Inc. (NASDAQ: BEAT) breached their fiduciary duties in connection with the proposed sale of the Company to Royal Philips...
  • 12/18/2020

Philips to Acquire BioTelemetry

  • MALVERN, Pa., Dec. 18, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ: BEAT) , the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that they have entered into a definitive merger agreement with Royal Philips (NYSE: PHG, AEX: PHIA).
  • 12/18/2020

BioTelemetry Has Sequential Upside Via Double-Digit Growth Into 2021

  • BioTelemetry has had a better than expected third quarter, leveraging new patient uptake plus clinician accounts in their healthcare and continuous care segments. Management have secured better lending terms on their revolving facility, and cash runaway is well over 2 years.
  • 11/17/2020

BioTelemetry's (BEAT) CEO Joseph Capper on Q3 2020 Results - Earnings Call Transcript

  • BioTelemetry's (BEAT) CEO Joseph Capper on Q3 2020 Results - Earnings Call Transcript
  • 10/29/2020

BioTelemetry, Inc. Reports Third Quarter 2020 Financial Results

  • Posts Record Quarterly Revenue Amidst Rapid Recovery Posts Record Quarterly Revenue Amidst Rapid Recovery
  • 10/29/2020

Global Telehealth Market Procurement Intelligence Report with COVID-19 Impact Analysis | Global Forecasts, 2020-2024

  • Telehealth market will register an incremental spend of about $11 billion, growing at a CAGR of 26.19% during the five-year forecast period.
  • 10/13/2020

Global Telemedicine Technologies Market to 2024 - Featuring American Well, Biotelemetry and Cerner Among Others - ResearchAndMarkets.com

  • The
  • 10/09/2020

Global Mobile Health App Market 2020: Industry Demand and Forecast to 2025 By Company Overview, Share, Size, Expansions, Agreements, New Product Launches and Growth Analysis

  • Oct 07, 2020 (The Expresswire) -- Global "Mobile Health App Market" 2020: - Mobile Health App Market report intends to offer inside and out data about Mobile...
  • 10/07/2020

$46.2 Billion Connected Medical Devices - Global Market Trajectory & Analytics to 2027 - ResearchAndMarkets.com

  • The
  • 10/02/2020

Financial Contrast: Aesthetic Medical International Holdings Group (NASDAQ:AIH) versus BioTelemetry (NASDAQ:BEAT)

  • Aesthetic Medical International Holdings Group (NASDAQ:AIH) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk. Valuation and Earnings This table compares Aesthetic Medical International Holdings Group and BioTelemetry’s […]
  • 09/28/2020

Stifel Financial Corp Has $1.13 Million Stock Position in BioTelemetry Inc (NASDAQ:BEAT)

  • Stifel Financial Corp lifted its stake in BioTelemetry Inc (NASDAQ:BEAT) by 25.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,062 shares of the medical research company’s stock after acquiring an additional 5,057 shares during the period. Stifel Financial […]
  • 09/24/2020

Telemedicine Market- Roadmap for Recovery from COVID-19|Demand For Digital Health Platforms to Boost the Market Growth | Technavio

  • The Global Telemedicine Market will grow by USD 56.47 bn during 2020-2024
  • 09/21/2020

Goldman Sachs Group Inc. Sells 63,245 Shares of BioTelemetry Inc (NASDAQ:BEAT)

  • Goldman Sachs Group Inc. lessened its holdings in shares of BioTelemetry Inc (NASDAQ:BEAT) by 29.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 150,633 shares of the medical research company’s stock after selling 63,245 shares during the period. Goldman Sachs Group Inc. owned 0.44% of BioTelemetry worth […]
  • 09/17/2020

World Markets for Mobile Cardiac Telemetry Systems, 2020-2026 - ScottCare Corporation is the Major Forerunner of the Industry - ResearchAndMarkets.com

  • The
  • 08/25/2020

Should You Investigate BioTelemetry, Inc. (NASDAQ:BEAT) At US$42.02?

  • BioTelemetry, Inc. (NASDAQ:BEAT), is not the largest company out there, but it received a lot of attention from a...
  • 08/07/2020

$106.67 Million in Sales Expected for BioTelemetry Inc (NASDAQ:BEAT) This Quarter

  • Wall Street brokerages forecast that BioTelemetry Inc (NASDAQ:BEAT) will post sales of $106.67 million for the current quarter, Zacks reports. Two analysts have provided estimates for BioTelemetry’s earnings, with the lowest sales estimate coming in at $105.83 million and the highest estimate coming in at $107.51 million. BioTelemetry reported sales of $111.29 million during the […]
  • 08/05/2020

BioTelemetry Inc (BEAT) Q2 2020 Earnings Call Transcript

  • Ladies and gentlemen, good afternoon, and thank you for joining us for the BioTelemetry Second Quarter 2020 Earnings Conference Call. Such statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company in the future, to be materially different from the statements that the company's executives may make today. It is now my pleasure to turn the floor over to your host, Mr. Joseph Capper, President and CEO of BioTelemetry.
  • 07/31/2020

BioTelemetry (BEAT) Beats Q2 Earnings and Revenue Estimates

  • BioTelemetry (BEAT) delivered earnings and revenue surprises of 191.67% and 15.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
  • 07/30/2020

BioTelemetry's (BEAT) CEO Joseph Capper on Q2 2020 Results - Earnings Call Transcript

  • BioTelemetry, Inc. (NASDAQ:BEAT) Q2 2020 Earnings Conference Call July 30, 2020 5:00 PM ET Company Participants Joseph Capper – President and Chief Executive Officer Heather Getz – Chief Financial Officer Conference Call Participants Kaila Krum – SunTrust Brooks O’Neil – Lake Street Capital Markets Bill Sutherland – The Benchmark Company Jayson Bedford – Raymond James Mitra Ramgopal – Sidoti Gene Mannheimer – Colliers Alex Silverman – AWM Investments Presentation Operator Good afternoon and thank you for joining us for the BioTelemetry Second Quarter 2020 Earnings Conference Call.
  • 07/30/2020

BioTelemetry, Inc. Reports Second Quarter 2020 Financial Results

  • Posts Strong Results and Ramps Up Business Development ActivityMALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter ended June 30, 2020. Company Highlights * Recognized quarterly total revenue of $99.1 million * Total revenue declined 11.4% year-over-year due to the impact of COVID-19 across most of our businesses * Reported quarterly GAAP net income of $2.3 million, or 2.3% of total revenue * Realized quarterly adjusted EBITDA of $25.6 million, or 25.8% of total revenue * Acquired Remote Patient Monitoring (“RPM”) assets from a subsidiary of Centene Corporation * Entered into Sales Agent Agreement with Boston Scientific * Assumed responsibility to service Roche’s remote INR patient basePresident and CEO CommentaryJoseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented:“Due to the unwavering commitment of the entire BioTelemetry team, we continued to successfully navigate the current external challenges.  As such, our business recovered faster than anticipated during the quarter, finishing strong with total revenue of $99.1 million and adjusted EBITDA of $25.6 million.  Cardiac monitoring volumes bounced off their April lows, quickly returning to more normalized levels by quarter end.  Given the encouraging trends coming out of the quarter, we believe we will soon be back to delivering year-over-year revenue and earnings growth.“As I shared previously, in early April we streamlined our cost structure to manage through the downturn.  As the business improved, we were able to call back all furloughed employees and are now operating at pre-pandemic headcount levels.  We have pivoted back into an offensive posture as evidenced by the advancement of several business initiatives.  The acquisition of Centene’s RPM assets is a key step toward increasing our commercial activity in the rapidly growing population health management market.  The Boston Scientific and Roche agreements are designed to extend the capabilities of our market-leading cardiac monitoring franchise.“We are more confident than ever that the post COVID-19 healthcare environment will demand a host of telehealth and remote monitoring solutions.  As one of the largest, fastest growing and most profitable connected health companies, we are perfectly positioned to capitalize on this opportunity.”Second Quarter Financial ResultsTotal revenue for the second quarter 2020 was $99.1 million compared to $111.8 million for the second quarter 2019, a decrease of $12.7 million, or 11.4%.Gross profit for the second quarter 2020 was $61.5 million, or 62.1% of total revenue, compared to $70.2 million, or 62.8% of total revenue, for the second quarter 2019.On a GAAP basis, net income for the second quarter 2020 was $2.3 million, or $0.06 per diluted share, compared to net income of $8.3 million, or $0.23 per diluted share, for the second quarter 2019.  The decline in net income was primarily due to the impact of COVID-19 on total revenue, partially offset by decreases in operating costs as we scaled back our operations due to the reduced demand.On an adjusted basis1, net income for the second quarter 2020 was $12.9 million, or $0.35 per diluted share.  This compares to adjusted net income of $19.4 million, or $0.53 per diluted share, for the second quarter 2019.  The decline in non-GAAP adjusted net income was consistent with the change in GAAP net income.  The details regarding adjusted net income are included in the reconciliation tables included in this release.1 The Company believes that providing non-GAAP financial measures offers a meaningful representation of our performance, as we exclude expenses that are not necessary to support our ongoing business.  We also make adjustments to facilitate year over year comparisons.  Please refer to our “Reconciliation of GAAP to Non-GAAP Financial Measures” in this release for additional information.Conference CallBioTelemetry, Inc. will host an earnings conference call on Thursday, July 30, 2020, at 5:00 PM Eastern Time.  The call will be webcast on the investor information page of our website, www.gobio.com/investors/events.  The call will be archived on our website for at least two weeks.About BioTelemetryBioTelemetry, Inc. is the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers.  More information can be found at www.gobio.com.Cautionary Statement Regarding Forward-Looking StatementsThis document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in our future.  These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning.  Examples of forward-looking statements include statements we make regarding the successful execution of our operating plan, including the success of the Sales Agent Agreement with Boston Scientific, our ability to increase demand for our products and services, to grow our market share and to recover from the impacts of the COVID-19 pandemic, our expectations regarding revenue trends in our segments, and our expectations regarding the growth and success related to the acquisition of Centene’s RPM assets and Roche’s remote INR patient base.  Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations.  These factors include, among other things: our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business; our ability to educate physicians and continue to obtain prescriptions for our products and services; changes to insurance coverage and reimbursement levels by Medicare and commercial payors for our products and services; our ability to attract and retain talented executive management and sales personnel; the commercialization of new competitive products; acceptance of our new products and services, such as our mobile cardiac telemetry patch; the impact of the COVID-19 pandemic; the impact of the October 2019 information technology incident; our ability to obtain and maintain required regulatory approvals for our products, services and manufacturing facilities; changes in governmental regulations and legislation; adverse regulatory actions; our ability to obtain and maintain adequate protection of our intellectual property; interruptions or delays in the telecommunications systems and/or information technology systems that we use; our ability to successfully resolve outstanding legal proceedings; and the other factors that are described in “Part I; Item 1A.  Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019, as well as the factors that are described in “Part II; Item 1A.  Risk Factors” of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.Contact:   BioTelemetry, Inc.    Heather C. Getz    Executive Vice President, Chief Financial and Administrative Officer    800-908-7103    investorrelations@gobio.com BioTelemetry, Inc. Consolidated Statements of Operations (unaudited) Three Months Ended Six Months Ended  June 30, June 30, (in thousands, except per share data)2020 2019 2020 2019 Revenue$89,407  $111,803  $202,438  $215,782  Other revenue9,702  —  9,702  —  Total revenue99,109  111,803  212,140  215,782  Cost of revenue37,582  41,563  80,105  80,764  Gross profit61,527  70,240  132,035  135,018  Gross profit %62.1% 62.8% 62.2% 62.6%          Operating expenses:        General and administrative31,099  30,587  62,980  58,194  Sales and marketing10,521  12,795  23,967  25,235  Credit loss expense6,166  5,379  12,186  10,527  Research and development2,699  3,532  6,267  6,865  Other charges5,003  2,234  7,087  5,304  Total operating expenses55,488  54,527  112,487  106,125           Income from operations6,039  15,713  19,548  28,893           Other expense:        Interest expense(1,702) (2,538) (3,809) (5,020) Loss on equity method investments—  (154) —  (186) Other non-operating income/(expense), net(1,400) 86  (469) (968) Total other expense, net(3,102) (2,606) (4,278) (6,174)          Income before income taxes2,937  13,107  15,270  22,719  Provision for income taxes(656) (4,807) (5,880) (2,734) Net income$2,281  $8,300  $9,390  $19,985           Net income per common share:        Basic$0.07  $0.25  $0.27  $0.59  Diluted$0.06  $0.23  $0.26  $0.55           Weighted average number of common shares outstanding:        Basic34,290  33,825  34,238  33,806  Diluted36,609  36,318  36,669  36,444  BioTelemetry, Inc.
  • 07/30/2020

BioTelemetry, Inc. Announces Sales Agent Agreement with Boston Scientific Corporation

  • Company expands portfolio of solutions with groundbreaking insertable cardiac monitor systemMALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced a sales agent agreement with Boston Scientific (NYSE:BSX), a global medical technology leader.  With this agreement, BioTelemetry becomes a sales agent in the United States for the Boston Scientific LUX-Dx™ Insertable Cardiac Monitor (ICM) System to an agreed upon subset of customers.  The LUX-Dx ICM System is the first ICM device with remote programming and also offers a dual-stage arrythmia detection algorithm.  BioTelemetry will discuss further details about the relationship during its second quarter earnings call scheduled for Thursday, July 30 at 5:00 p.m. Eastern.  BioTelemetry is the market leader in the wearable cardiac diagnostic monitoring space and provides its Independent Diagnostic Testing Facility (IDTF) services to customers that do not have the capacity or capability to monitor their device patients.  This sales agent agreement adds ICM to its already diverse device portfolio of Holter, Extended Holter and Event monitors, and its flagship Mobile Cardiac Outpatient Telemetry (MCOT™) monitor.  The United States ICM market is large and growing, and with this solution, both companies can access an expanded customer base while maintaining focus on their core businesses.“We are delighted to work with Boston Scientific and a team that is as committed as we are about improving the lives of the people we serve,” said Joseph H. Capper, President and CEO of BioTelemetry.  “Together, we are delivering solutions that leverage our collective expertise, and providing access to a full portfolio of flexible cardiac care solutions to meet physician and patient needs in an unprecedented way.” BioTelemetry processes over four billion heartbeats per day and monitors over one million patients each year.  It is the pioneer in remote patient monitoring, revolutionizing healthcare with its suite of cardiac monitoring devices and cloud-based vendor-neutral remote monitoring platform, including its FDA-cleared ePatch™ and MCOT™ monitors.  BioTelemetry advances health by providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner.About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers.  More information can be found at www.gobio.com.Heather C. Getz Investor Relations Executive Vice President, Chief Financial Officer 800-908-7103 investorrelations@biotelinc.com Amy M. Knapp Media Relations Vice President, Corporate Communications 813-277-8456 amy.knapp@gobio.com
  • 07/30/2020

The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter

  • Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Adamis Pharmaceuticals Corp (NASDAQ: ADMP) Annexon...
  • 07/30/2020

BioTelemetry, Inc. Acquires Remote Patient Monitoring Platform from Centene Subsidiary

  • Expands relationship to serve Centene membersMALVERN, Pa., July 29, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced it has acquired the On.Demand™ remote patient monitoring (RPM) and coaching platform, operated by Envolve People Care, Inc., a Centene Corporation subsidiary.  This acquisition adds chronic RPM and coaching solutions to BioTelemetry’s current suite of acute care connected health products and services, focusing specifically on diabetes, hypertension and chronic heart failure.  As part of this acquisition, and under the companies’ strategic partnership agreement, BioTelemetry becomes the exclusive provider of diabetes RPM services to Centene Medicaid members currently utilizing, implementing or engaged to implement the platform in 2020.  In addition to Centene, BioTelemetry will partner externally with payor, provider and employer organizations to improve health outcomes, reduce costs and eliminate waste using On.Demand’s targeted monitoring and coaching interventions.“We are excited to add On.Demand to our connected health portfolio,” said Joseph H. Capper, President and CEO of BioTelemetry.  “This acquisition uniquely positions BioTelemetry to deliver population health solutions at a time when remote and telehealth options are increasingly important in improving effectiveness across the healthcare continuum.  We are delighted to partner with an organization like Centene, which has demonstrated a clear commitment to improving the lives of so many people and communities.”On.Demand is a mHealth solution that combines real-time monitoring of biometric data with cellular- and web-based technology, proactive and reactive health coaching, population health reporting and customizable interventions.  The platform is designed to supplement a physician’s care plan by increasing patient engagement, improving compliance and reducing costs.  It matches people to the clinical expertise and condition management tools they need when they need them, providing intervention and triage that helps bridge the gap between patient visits.  In addition, the platform also includes Alexa Skill.  On.Demand users are able to schedule coaching appointments, access educational resources, set reminders, and receive real-time assessments and immediate referrals for mental and physical health needs.BioTelemetry is the pioneer in patient care monitoring, providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects more efficiently, accurately and cost-effectively.  Through its connected health solutions, population health management platform and support of some of the largest clinical trials, BioTelemetry is advancing health and improving lives.  BioTelemetry’s suite of services and devices expand across cardiac outpatient telemetry, diabetes, hypertension and weight management.About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers.  More information can be found at www.gobio.com.Heather C. Getz Investor Relations Executive Vice President, Chief Financial Officer 800-908-7103 investorrelations@biotelinc.comAmy M. Knapp Media Relations Vice President, Corporate Communications 813-277-8456 amy.knapp@gobio.com
  • 07/29/2020

The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings

  • Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from...
  • 07/26/2020

BioTelemetry, Inc. to Release Second Quarter 2020 Earnings Results on July 30, 2020

  • MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2020 earnings on Thursday, July 30 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Thursday, July 30, 2020.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on the website for two weeks.About BioTelemetry BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care.  We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers.  More information can be found at www.gobio.com.Contact: BioTelemetry, Inc. Heather C. Getz Investor Relations Executive Vice President, Chief Financial Officer 800-908-7103 InvestorRelations@biotelinc.com
  • 07/23/2020

10,802 Shares in BioTelemetry Inc (NASDAQ:BEAT) Purchased by Advisor Group Holdings Inc.

  • Advisor Group Holdings Inc. acquired a new position in BioTelemetry Inc (NASDAQ:BEAT) during the 1st quarter, according to its most recent filing with the SEC. The fund acquired 10,802 shares of the medical research company’s stock, valued at approximately $417,000. Other institutional investors have also added to or reduced their stakes in the company. APG […]
  • 07/16/2020

Royal Bank of Canada Grows Stake in BioTelemetry Inc (NASDAQ:BEAT)

  • Royal Bank of Canada grew its stake in shares of BioTelemetry Inc (NASDAQ:BEAT) by 353.2% in the first quarter, Holdings Channel reports. The fund owned 47,731 shares of the medical research company’s stock after acquiring an additional 37,199 shares during the quarter. Royal Bank of Canada’s holdings in BioTelemetry were worth $1,838,000 as of its […]
  • 07/11/2020

Why Biotechs Are Moving Up Among 4 Top-Rated Health Care Stocks

  • The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
  • 07/10/2020

Is BioTelemetry, Inc. (BEAT) A Good Stock To Buy?

  • Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
  • 07/05/2020

State of Tennessee Treasury Department Grows Stock Position in BioTelemetry Inc (NASDAQ:BEAT)

  • State of Tennessee Treasury Department lifted its stake in BioTelemetry Inc (NASDAQ:BEAT) by 3.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 22,843 shares of the medical research company’s stock after purchasing an additional 864 shares during the period. State of […]
  • 07/05/2020

Squarepoint Ops LLC Purchases Shares of 9,600 BioTelemetry Inc (NASDAQ:BEAT)

  • Squarepoint Ops LLC purchased a new stake in shares of BioTelemetry Inc (NASDAQ:BEAT) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 9,600 shares of the medical research company’s stock, valued at approximately $370,000. A number of other institutional investors and hedge […]
  • 07/04/2020

The Global Cardiac Safety Services Market is expected to grow from USD 453.08 Million in 2019 to USD 830.62 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 10.62%

  • Market Segmentation & Coverage: This research report categorizes the Cardiac Safety Services to forecast the revenues and analyze the trends in each of the following sub-markets:
  • 06/24/2020

BioTelemetry Inc (NASDAQ:BEAT) Shares Acquired by Alliancebernstein L.P.

  • Alliancebernstein L.P. lifted its holdings in shares of BioTelemetry Inc (NASDAQ:BEAT) by 13.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 129,810 shares of the medical research company’s stock after buying an additional 15,210 shares during the quarter. Alliancebernstein […]
  • 06/23/2020

$137+ Billion mHealth Monitoring Diagnostic Medical Devices Market Outlook, 2027 - ResearchAndMarkets.com

  • The
  • 06/23/2020

BioTelemetry Inc (NASDAQ:BEAT) Expected to Post Quarterly Sales of $85.93 Million

  • Brokerages expect BioTelemetry Inc (NASDAQ:BEAT) to report $85.93 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for BioTelemetry’s earnings, with the lowest sales estimate coming in at $84.58 million and the highest estimate coming in at $87.27 million. BioTelemetry reported sales of $111.80 million during the same quarter […]
  • 06/21/2020

Assessment of COVID-19's Effect on Holter Monitor Market 2020-2024 | Increasing Prevalence of Cardiac Disorders to Augment Growth | Technavio

  • The Global Holter Monitor Market will grow by USD 176.83 mn during 2020-2024
  • 06/18/2020

Global Telemedicine Services Market To Reach Value Of $78 Billion In 2023

  • Telemedicine Services Market Global Report 2020-30: Covid 19 Growth And Change
  • 06/12/2020

BioTelemetry Inc (NASDAQ:BEAT) Shares Sold by Principal Financial Group Inc.

  • Principal Financial Group Inc. cut its position in shares of BioTelemetry Inc (NASDAQ:BEAT) by 3.8% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 264,075 shares of the medical research company’s stock after selling 10,479 shares during the quarter. Principal Financial Group Inc. owned 0.77% […]
  • 06/10/2020

BioTelemetry: Still Undervalued Despite Pandemic Headwinds (NASDAQ:BEAT)

  • BioTelemetry presents a strong investment case despite being in danger of finally breaking a cycle of 30+ consecutive quarters of top line revenue growth. In fa
  • 06/08/2020

Why Coronavirus Test Firms Are Among 4 Key Health Care Stocks

  • The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
  • 06/05/2020

Edited Transcript of BEAT earnings conference call or presentation 6-May-20 9:00pm GMT

  • Q1 2020 BioTelemetry Inc Earnings Call
  • 06/04/2020

Digital Health Monitoring Devices Market Analysis as per the Latest Coronavirus Impact

  • Jun 01, 2020 (Heraldkeepers) -- New York, June 01, 2020: Market Research Engine has published a new report titled as "Digital Health Monitoring Devices...
  • 06/01/2020

Research Report with COVID-19 Forecasts - Wearable Medical Devices Market 2020-2024 | Increasing Prevalence of Chronic Diseases to Boost Growth | Technavio

  • The wearable medical devices market size has the potential to grow by USD 10.24 billion during 2020-2024
  • 05/25/2020

Outlook on the Worldwide ECG Monitors Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

  • The
  • 05/20/2020

Why This Coronavirus Testing Outlet Is Among 3 Key Plays

  • The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
  • 05/08/2020

BioTelemetry Inc (BEAT) Q1 2020 Earnings Call Transcript

  • Image source: The Motley Fool. BioTelemetry Inc (NASDAQ: BEAT)Q1 2020 Earnings CallMay 6, 2020, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorThank you for joining us for the Biotelemetry First Quarter 2020 Earnings Conference Call.
  • 05/07/2020

U.S. RESEARCH ROUNDUP-Ashland Global, Lyft, Solaredge Technologies

  • Wall Street securities analysts on Thursday revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies. HIGHLIGHTS * Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight * Lyft Inc : Piper Sandler cuts to neutral from overweight * Natera Inc : JP Morgan raises to overweight from neutral * Occidental Petroleum Corp : SunTrust Robinson raises to hold from sell * Solaredge Technologies : Canaccord Genuity cuts to hold from buy Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order. * A. O. Smith Corp : Stephens raises target price to $40 from $37 * Acadia Healthcare Company Inc : Citigroup cuts price target to $34 from $37 * Acadia Healthcare Company Inc : Deutsche Bank cuts target price to $28 from $32 * Activision Blizzard Inc : Keybanc raises target price to $80 from $68 * Adient Plc : Deutsche Bank raises target price to $20 from $15 * ADMA Biologics Inc : Oppenheimer cuts target price to $7 from $14 * Advanced Energy Industries Inc : Citigroup raises price target to $63 from $40 * Advanced Energy Industries Inc : Cowen and Company raises PT to $58 from $51 * Advanced Energy Industries Inc : D.A. Davidson raises target to $60 from $50 * Advanced Energy Industries Inc : Susquehanna cuts target price to $85 from $90 * Aerie Pharmaceuticals Inc : H.C. Wainwright cuts target price to $31 from $37 * Aerie Pharmaceuticals Inc : Mizuho cuts target price to $29 from $34 * Aerie Pharmaceuticals Inc : Piper Sandler cuts target price to $35 from $45 * Aerie Pharmaceuticals Inc : SunTrust Robinson cuts price target to $22 from $26 * Agco Corp : Stephens raises target price to $65 from $60 * Air Transport Services Group Inc : Cowen and Company raises PT to $26 from $25 * Albemarle Corp : UBS cuts target price to $90 from $98 * Alexion Pharmaceuticals Inc : BMO cuts target price to $142 from $147 * Alexion Pharmaceuticals Inc : Credit Suisse cuts target price to $142 from $147 * Alexion Pharmaceuticals Inc : Jefferies cuts price target to $111 from $112 * Alexion Pharmaceuticals Inc : Raymond James cuts target price to $156 from $159 * Alexion Pharmaceuticals Inc : SunTrust Robinson cuts target to $135 from $141 * Alexion Pharmaceuticals Inc : SVB Leerink cuts target price to $150 from $156 * Allegiant Travel Co : Cowen and Company cuts price target to $74 from $100 * Allete Inc : Guggenheim cuts price target to $65 from $70 * Allogene Therapeutics Inc : Jefferies raises target price to $37 from $36 * Allstate Corp : Piper Sandler raises target price to $112 from $108 * Alnylam Pharmaceuticals Inc : Guggenheim raises price target to $166 from $155 * Alnylam Pharmaceuticals Inc : BMO raises target price to $171 from $145 * Alnylam Pharmaceuticals Inc : Jefferies raises price target to $165 from $142 * Alnylam Pharmaceuticals Inc : JP Morgan cuts to neutral from overweight * Alnylam Pharmaceuticals Inc : JP Morgan raises target price to $137 from $133 * Alnylam Pharmaceuticals Inc : Needham raises target price to $160 from $135 * Alnylam Pharmaceuticals Inc : Oppenheimer raises target price to $162 from $140 * Alnylam Pharmaceuticals Inc : Piper Sandler raises target to $169 from $142 * Alteryx Inc : Citigroup cuts price target to $147 from $160 * Alteryx Inc : Cowen and Company cuts target price to $135 from $145 * Alteryx Inc : Needham cuts target price to $140 from $152 * Alteryx Inc : Wedbush cuts price target to $138 from $146 * Amedisys Inc : Benchmark cuts to hold rating * Ameriprise Financial Inc : Evercore ISI raises target price to $139 from $136 * Ametek Inc : Berenberg raises target price to $93 from $86 * Ametek Inc : Stephens cuts target price to $92 from $94 * Anaptysbio Inc : Credit Suisse raises target price to $16 from $14 * Apache Corp : Credit Suisse raises target price to $10 from $4 * Aptiv Plc : Deutsche Bank raises target price to $75 from $59 * Arcus Biosciences Inc : Wedbush raises target price to $40 from $26 * Ares Capital Corp : BMO cuts target price by $5 to $16 * Ares Capital Corp : Citigroup raises price target to $15 from $13 * Ares Management Corp : BMO raises target price to $40 from $30 * Ares Management Corp : Credit Suisse raises target price to $40 from $38 * Ares Management Corp : Jefferies raises target price to $42 from $39 * Ares Management Corp : KBW raises target price to $45 from $44 * ASGN Inc : Jefferies raises target price to $54 from $31 * Ashland Global Holdings Inc : Deutsche Bank raises target price to $70 from $65 * Ashland Global Holdings Inc. : JP Morgan cuts target price to $62 from $68 * Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight * Ashland Global Holdings Inc. : SunTrust Robinson cuts price target to $75 from $87 * Aspen Technology Inc : Benchmark cuts target price to $130 * Aspen Technology Inc : Keybanc raises target price to $120 from $110 * Assetmark Financial Holdings Inc : BMO cuts target price to $23 from $26 * Assurant Inc : SunTrust Robinson cuts price target to $145 from $155 * Astronics Corp : Canaccord Genuity cuts target price to $10 from $14 * Astronics Corp : SunTrust Robinson cuts price target to $6 from $7 * Atkore International Group Inc : Citigroup raises price target to $26 from $24 * Atlas Corp (British Columbia) : Citigroup cuts price target to $7 from $12 * Avanos Medical Inc : Berenberg raises target price to $33 from $30 * Avanos Medical Inc : Stephens raises target price to $38 from $30 * Axalta Coating Systems Ltd : Citigroup raises price target to $21 from $18 * Axalta Coating Systems Ltd : Credit Suisse cuts target price to $27 from $29 * Axalta Coating Systems Ltd : Jefferies raises target price to $18 from $15 * Axalta Coating Systems Ltd : Keybanc raises target price to $24 from $23 * Axcelis Technologies Inc : D.A. Davidson raises price target to $25 from $20 * Axcella Health Inc : BTIG raises target price to $12 from $10 * Axogen Inc : Canaccord Genuity cuts target price to $12 from $22 * Axogen Inc : Jefferies cuts target price to $21 from $30 * Bank of N.T. Butterfield & Son Ltd : Citigroup raises target to $21 from $15 * Barrett Business Services Inc : Barrington Research raises PT to $52 from $48 * Barrick Gold Corp : Deutsche Bank raises target price to $34 from $25 * Benefitfocus Inc : Piper Sandler cuts target price to $26 from $35 * Bio Rad Laboratories Inc : Citigroup raises price target to $525 from $480 * Bio Rad Laboratories Inc : Jefferies raises target price to $525 from $500 * Biocryst Pharmaceuticals Inc : Jefferies raises price target to $9 from $8 * Biocryst Pharmaceuticals Inc : Piper Sandler raises target price to $10 from $8 * Biotelemetry Inc : Benchmark cuts target price to $52 from $55 * Black Knight Inc : KBW raises target price to $70 from $68 * Black Knight Inc : Stephens raises target price to $88 from $84 * Black Knight Inc : Wedbush raises target price to $70 from $66 * Black Stone Minerals LP : Simmons Energy raises target price to $8 from $5 * Blackbaud Inc : Evercore ISI cuts target price to $48 from $55 * Blucora Inc : Benchmark cuts price target to $25 from $37 * BMC stock Holdings Inc : Stephens raises target price to $25 from $22 * BMC stock Holdings Inc : SunTrust Robinson raises price target to $26 from $22 * BorgWarner Inc : Jefferies raises target price to $33 from $30 * BorgWarner Inc : JP Morgan raises price target to $35 from $32 * BorgWarner Inc : Oppenheimer cuts target price to $44 from $45 * BorgWarner Inc : RBC raises target price to $31 from $29 * Boston Private Financial Holdings Inc : Piper Sandler raises PT to $7 from $6.
  • 05/07/2020

Edited Transcript of BEAT earnings conference call or presentation 6-May-20 9:00pm GMT

  • Q1 2020 BioTelemetry Inc Earnings Call
  • 05/07/2020

BioTelemetry Withdraws FY20 Guidance

  • 05/06/2020

BioTelemetry Q1 Adj. EPS $0.450 Beats $0.430 Estimate, Sales $113.031M Miss $113.110M Estimate

  • 05/06/2020

BioTelemetry, Inc. Reports First Quarter 2020 Financial Results

  • MALVERN, Pa., May 06, 2020 -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality.
  • 05/06/2020

The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

  • Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...
  • 05/06/2020

The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

  • Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
  • 05/03/2020

How Does BioTelemetry’s (NASDAQ:BEAT) P/E Compare To Its Industry, After Its Big Share Price Gain?

  • BioTelemetry (NASDAQ:BEAT) shares have had a really impressive month, gaining 33%, after some slippage. But...
  • 05/01/2020

What Is BioTelemetry's (NASDAQ:BEAT) P/E Ratio After Its Share Price Rocketed?

  • BioTelemetry (NASDAQ:BEAT) shareholders are no doubt pleased to see that the share price has had a great month...
  • 05/01/2020

BioTelemetry, Inc. to Release First Quarter 2020 Earnings Results on May 6, 2020

  • MALVERN, Pa., April 29, 2020 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2020 earnings on Wednesday, May 6 at 4:00 PM Eastern Time. The BioTelemetry.
  • 04/29/2020

BioTelemetry, Inc. to Release First Quarter 2020 Earnings Results on May 6, 2020

  • MALVERN, Pa., April 29, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2020 earnings on Wednesday, May 6 at...
  • 04/29/2020

BioTelemetry (NASDAQ:BEAT) Downgraded by Zacks Investment Research to Hold

  • BioTelemetry (NASDAQ:BEAT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday, Zacks.com reports. According to Zacks, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart […]
  • 04/29/2020

BioTelemetry, Inc. to Release First Quarter —…—… Earnings Results on May 6, —…—…

  • 04/29/2020

BioTelemetry, Inc. to Move to Virtual-only Annual Stockholder Meeting for 2020

  • BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that its 2020 Annual Meeting of Stockholders will be held virtually, moving away from an in-person event due to the evolving nature of the COVID-19 pandemic. Stockholders of record at the close of business March 10, 2020, are invited to vote their shares and register for the meeting at www.virtualshareholdermeeting.com/BEAT2020 using the instructions provided with their proxy materials that were issued beginning March 24, 2020. Stockholders may submit questions in advance when they register for the meeting, and they also will have the opportunity to submit questions during the virtual event using the directions on the meeting website that day.
  • 04/27/2020

BioTelemetry, Inc. to Move to Virtual-onlyAnnual Stockholder Meeting for 2020

  • MALVERN, Pa., April 27, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery...
  • 04/27/2020

How Much is BioTelemetry, Inc.’s (NASDAQ:BEAT) CEO Getting Paid?

  • Joe Capper became the CEO of BioTelemetry, Inc. (NASDAQ:BEAT) in 2010. This report will, first, examine the CEO...
  • 04/27/2020

Deutsche Bank Says Results Will Beat Forecasts

  • Deutsche Bank says results will beat forecasts
  • 04/27/2020

VR Game 'Supernatural' Brings Fitness Gaming To Another Level; Step Aside, 'Beat Saber'

  • TLDR: 'Supernatural' will make you want to work out often.
  • 04/24/2020

Stock Upgrades: BioTelemetry Shows Rising Relative Strength

  • 04/24/2020

Stocks Slip Again on Oil Prices

  • Stocks Slip Again on Oil Prices
  • 04/22/2020

Is a Surprise Coming for BioTelemetry (BEAT) This Earnings Season?

  • BioTelemetry (BEAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
  • 04/22/2020

Is a Surprise Coming for BioTelemetry (BEAT) This Earnings Season?

  • BioTelemetry (BEAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
  • 04/22/2020

Is a Surprise Coming for BioTelemetry (BEAT) This Earnings Season?

  • 04/22/2020

BioTelemetry Inc (NASDAQ:BEAT) Short Interest Update

  • BioTelemetry Inc (NASDAQ:BEAT) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 2,240,000 shares, a decrease of 16.6% from the March 15th total of 2,686,100 shares. Based on an average daily volume of 341,900 shares, the short-interest ratio is currently […]
  • 04/20/2020

BioTelemetry Inc (NASDAQ:BEAT) Shares Sold by Nuveen Asset Management LLC

  • Nuveen Asset Management LLC trimmed its holdings in BioTelemetry Inc (NASDAQ:BEAT) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 193,762 shares of the medical research company’s stock after selling 768 shares during the period. Nuveen Asset Management LLC owned […]
  • 04/19/2020

Norges Bank Invests $19.69 Million in BioTelemetry Inc (NASDAQ:BEAT)

  • Norges Bank purchased a new stake in shares of BioTelemetry Inc (NASDAQ:BEAT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 425,275 shares of the medical research company’s stock, valued at approximately $19,690,000. A number of other large investors have also recently bought and […]
  • 04/18/2020

BioTelemetry (NASDAQ:BEAT) Downgraded to Hold at Zacks Investment Research

  • Zacks Investment Research downgraded shares of BioTelemetry (NASDAQ:BEAT) from a buy rating to a hold rating in a research report released on Wednesday, Zacks.com reports. According to Zacks, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of cardiac arrhythmias, or […]
  • 04/18/2020

Google is Making A Smart Debit Card, Reports Claim; Will It Beat Apple's Cash Card?

  • Cash, check, or Google Card?
  • 04/17/2020

  • Lot Sixteen adds 4 — Franchises lobby Treasury to change small business loan rules
  • 04/16/2020

BioTelemetry (BEAT) to Report Q1 Results: Wall Street Expects Earnings Growth

  • BioTelemetry (BEAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 04/16/2020

BioTelemetry (BEAT) to Report Q1 Results: Wall Street Expects Earnings Growth

  • BioTelemetry (BEAT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  • 04/16/2020

BioTelemetry (NASDAQ:BEAT) Rating Increased to Buy at Zacks Investment Research

  • BioTelemetry (NASDAQ:BEAT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Zacks.com reports. The firm currently has a $46.00 target price on the medical research company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 3.56% from the company’s current price. According […]
  • 04/16/2020

How Does BioTelemetry's (NASDAQ:BEAT) P/E Compare To Its Industry, After Its Big Share Price Gain?

  • Those holding BioTelemetry (NASDAQ:BEAT) shares must be pleased that the share price has rebounded 37% in the last...
  • 04/16/2020

Exchange Traded Concepts LLC Increases Stake in BioTelemetry Inc (NASDAQ:BEAT)

  • Exchange Traded Concepts LLC lifted its stake in shares of BioTelemetry Inc (NASDAQ:BEAT) by 90.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,219 shares of the medical research company’s stock after acquiring an additional 1,532 shares during the […]
  • 04/16/2020

BioTelemetry (BEAT) to Report Q1 Results: Wall Street Expects Earnings Growth

  • 04/16/2020

Hedge Funds Are Betting On KEMET Corporation (KEM)

  • We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
  • 04/15/2020

Is Brinker International, Inc. (EAT) A Good Stock To Buy?

  • We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
  • 04/15/2020

Huron Consulting Group (HURN): Hedge Funds Are Snapping Up

  • We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
  • 04/15/2020

Hedge Funds Are Selling BioTelemetry, Inc. (BEAT)

  • We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
  • 04/15/2020

Geode Capital Management LLC Raises Holdings in BioTelemetry Inc (NASDAQ:BEAT)

  • Geode Capital Management LLC boosted its stake in BioTelemetry Inc (NASDAQ:BEAT) by 3.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 466,400 shares of the medical research company’s stock after buying an additional 14,750 shares during the quarter. Geode Capital Management LLC owned […]
  • 04/15/2020

Ladenburg Thalmann Financial Services Inc. Sells 534 Shares of BioTelemetry Inc (NASDAQ:BEAT)

  • Ladenburg Thalmann Financial Services Inc. decreased its position in shares of BioTelemetry Inc (NASDAQ:BEAT) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,088 shares of the medical research company’s stock after selling 534 shares during the […]
  • 04/15/2020

Should You Be Concerned About BioTelemetry, Inc.’s (NASDAQ:BEAT) Historical Volatility?

  • Anyone researching BioTelemetry, Inc. (NASDAQ:BEAT) might want to consider the historical volatility of the share...
  • 04/15/2020

Piano Van: Hong Kong Music Lessons Go Mobile To Beat Virus

  • Piano van: Hong Kong music lessons go mobile to beat virus
  • 04/15/2020

Were Hedge Funds Right About Chesapeake Utilities Corporation (CPK)?

  • We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
  • 04/14/2020

Reilly Financial Advisors LLC Purchases Shares of 4,700 BioTelemetry Inc (NASDAQ:BEAT)

  • Reilly Financial Advisors LLC purchased a new stake in BioTelemetry Inc (NASDAQ:BEAT) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,700 shares of the medical research company’s stock, valued at approximately $181,000. A number of other hedge funds and other institutional investors […]
  • 04/14/2020

$114.42 Million in Sales Expected for BioTelemetry Inc (NASDAQ:BEAT) This Quarter

  • Wall Street brokerages expect BioTelemetry Inc (NASDAQ:BEAT) to post $114.42 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for BioTelemetry’s earnings, with the lowest sales estimate coming in at $114.11 million and the highest estimate coming in at $114.74 million. BioTelemetry reported sales of $103.98 million in the […]
  • 04/13/2020

BioTelemetry Inc (NASDAQ:BEAT) Shares Sold by Bank of America Corp DE

  • Bank of America Corp DE trimmed its stake in BioTelemetry Inc (NASDAQ:BEAT) by 2.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 123,370 shares of the medical research company’s stock after selling 3,525 shares during the quarter. Bank of America Corp DE’s holdings in BioTelemetry were worth $5,712,000 at the end of the most […]
  • 04/12/2020

Janus Henderson Group PLC Purchases 1,076 Shares of BioTelemetry Inc (NASDAQ:BEAT)

  • Janus Henderson Group PLC boosted its position in shares of BioTelemetry Inc (NASDAQ:BEAT) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,726 shares of the medical research company’s stock after purchasing an additional 1,076 shares during the […]
  • 04/08/2020

Goldman Sachs Group Inc. Boosts Position in BioTelemetry Inc (NASDAQ:BEAT)

  • Goldman Sachs Group Inc. raised its stake in shares of BioTelemetry Inc (NASDAQ:BEAT) by 28.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 138,609 shares of the medical research company’s stock after buying an additional 30,811 shares during the quarter. Goldman Sachs Group […]
  • 04/08/2020

U.S. Patient Monitoring Devices Market (2020 to 2026) - Favorable Reimbursement Policies Present Opportunities - ResearchAndMarkets.com

  • The "U.S. Patient Monitoring Devices Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • 04/08/2020

Meet Mu6: How This Noise Canceling Headphones Can Beat the All-Time Classic Bose

  • The most affordable noice-canceling headphones out there!
  • 04/07/2020

BioTelemetry, Inc. Names Dr. Andrei Stoica Chief Technology Officer

  • BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Dr. Andrei Stoica has been named Chief Technology Officer of the company. Dr. Stoica will lead the company’s global technology and product development operations, reporting to Joseph H. Capper, President and Chief Executive Officer.
  • 04/07/2020

BioTelemetry, Inc. Names Dr. Andrei Stoica Chief Technology Officer

  • MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery...
  • 04/07/2020

Bank of New York Mellon Corp Boosts Holdings in BioTelemetry Inc (NASDAQ:BEAT)

  • Bank of New York Mellon Corp grew its position in BioTelemetry Inc (NASDAQ:BEAT) by 3.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 407,400 shares of the medical research company’s stock after buying an additional 14,735 shares during the […]
  • 04/07/2020

Jane Street Group LLC Buys New Position in BioTelemetry Inc (NASDAQ:BEAT)

  • Jane Street Group LLC bought a new stake in shares of BioTelemetry Inc (NASDAQ:BEAT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,858 shares of the medical research company’s stock, valued at approximately $410,000. Several other institutional investors have […]
  • 04/06/2020

Insights into the Patient Monitoring Devices Market in the United States to 2026 - Profiling Abbott Laboratories, Bio Telemetry & Dexcom Among Others

  • Dublin, April 06, 2020 -- The "U.S. Patient Monitoring Devices Market - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering..
  • 04/06/2020

BioTelemetry Inc (NASDAQ:BEAT) Holdings Raised by Man Group plc

  • Man Group plc grew its stake in shares of BioTelemetry Inc (NASDAQ:BEAT) by 24.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 108,397 shares of the medical research company’s stock after purchasing an additional 21,219 shares during the period. […]
  • 04/05/2020

Is It Time To Consider Buying BioTelemetry, Inc. (NASDAQ:BEAT)?

  • BioTelemetry, Inc. (NASDAQ:BEAT), which is in the healthcare business, and is based in United States, led the NASDAQGS...
  • 04/03/2020

U.S. Patient Monitoring Devices Market - Forecast to 2026

  • Patient monitoring devices provide assistance in continuous measurement of a patient's health parameter such as heart rate, respiratory rate, blood pressure, blood oxygen saturation and many other parameters which has become a common feature of all healthcare settings.Read the full report: https:
  • 04/02/2020

Brinker Capital Inc. Grows Stake in BioTelemetry Inc (NASDAQ:BEAT)

  • Brinker Capital Inc. increased its holdings in shares of BioTelemetry Inc (NASDAQ:BEAT) by 18.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,382 shares of the medical research company’s stock after purchasing an additional 3,149 shares during the quarter. Brinker Capital […]
  • 04/01/2020

Advisor Group Inc. Sells 1,738 Shares of BioTelemetry Inc (NASDAQ:BEAT)

  • Advisor Group Inc. reduced its position in BioTelemetry Inc (NASDAQ:BEAT) by 32.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,557 shares of the medical research company’s stock after selling 1,738 shares during the quarter. Advisor Group Inc.’s holdings in BioTelemetry were worth […]
  • 04/01/2020

Short Interest in BioTelemetry Inc (NASDAQ:BEAT) Rises By 7.0%

  • BioTelemetry Inc (NASDAQ:BEAT) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totalling 2,686,100 shares, an increase of 7.0% from the February 27th total of 2,510,000 shares. Based on an average trading volume of 383,600 shares, the days-to-cover ratio is presently […]
  • 04/01/2020

Nomura warns of mass unemployment, social unrest if coronavirus “beats us”

  • Negative global GDP growth rate estimate is concerning, but what is even more dreadful is Nomura’s bad scenario where coronavirus “beats us.”
  • 03/31/2020

Q1 2020 EPS Estimates for BioTelemetry Inc (NASDAQ:BEAT) Reduced by Dougherty & Co

  • BioTelemetry Inc (NASDAQ:BEAT) – Dougherty & Co decreased their Q1 2020 earnings estimates for shares of BioTelemetry in a research report issued to clients and investors on Monday, March 30th. Dougherty & Co analyst G. Mannheimer now expects that the medical research company will earn $0.44 per share for the quarter, down from their prior […]
  • 03/31/2020

BioTelemetry (NASDAQ:BEAT) Upgraded at BidaskClub

  • BioTelemetry (NASDAQ:BEAT) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, BidAskClub reports. A number of other equities analysts also recently commented on BEAT. Zacks Investment Research downgraded shares of BioTelemetry from a “hold” rating to a “sell” rating in a […]
  • 03/31/2020

Amalgamated Bank Purchases 444 Shares of BioTelemetry Inc (NASDAQ:BEAT)

  • Amalgamated Bank grew its position in BioTelemetry Inc (NASDAQ:BEAT) by 7.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,634 shares of the medical research company’s stock after purchasing an additional 444 shares during the quarter. Amalgamated Bank’s holdings in BioTelemetry […]
  • 03/30/2020

How Does BioTelemetry's (NASDAQ:BEAT) P/E Compare To Its Industry, After The Share Price Drop?

  • To the annoyance of some shareholders, BioTelemetry (NASDAQ:BEAT) shares are down a considerable 32% in the last...
  • 03/27/2020

BioTelemetry Earlier Reported Expanded Mobile Cardiac Outpatient Telemetry Service To Monitor QT Prolongation In Coronavirus Patients

  • 03/25/2020

BRIEF-Biotelemetry Expands MCOT Service To Monitor Life-Threatening QT Prolongation In COVID-19 Patients

  • BioTelemetry Inc:
  • 03/25/2020

BIOTELEMETRY, INC. EXPANDS MCOT™ SERVICE TO MONITOR LIFE-THREATENING QT PROLONGATION IN COVID-19 PATIENTS

  • BioTelemetry, Inc. (BEAT), a leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced the activation of an expanded service using its Mobile Cardiac Outpatient Telemetry (MCOT™) to monitor life-threatening QT prolongation in COVID-19 patients. As a reminder, MCOT is the most accurate and studied arrhythmia monitoring detection system in the market. Certain medications being used in the treatment of COVID-19 patients, including hydroxychloroquine and azithromycin, can cause an abnormality in the heart’s electrical system known as QT prolongation; this serious condition can unfortunately lead to sudden cardiac arrest or death.
  • 03/25/2020

BIOTELEMETRY, INC. EXPANDS MCOT™ SERVICE TO MONITOR LIFE-THREATENING QT PROLONGATION IN COVID-19 PATIENTS

  • Only remote cardiac monitoring company whose proprietary connected system has FDA-approved indication to measure, analyze and report QT interval
  • 03/25/2020

Global Cardiovascular Disease Monitoring and Diagnostic Devices Market Forecast to Grow by US$1.2 Billion, Driven by a CAGR of 7%

  • The "Cardiovascular Disease Monitoring and Diagnostic Devices - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • 03/24/2020

BioTelemetry Inc (NASDAQ:BEAT) Stake Lessened by Raymond James & Associates

  • Raymond James & Associates cut its stake in BioTelemetry Inc (NASDAQ:BEAT) by 7.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,622 shares of the medical research company’s stock after selling 6,371 shares during the period. Raymond James & Associates […]
  • 03/23/2020

BioTelemetry (NASDAQ:BEAT) Price Target Lowered to $55.00 at Benchmark

  • BioTelemetry (NASDAQ:BEAT) had its price target decreased by Benchmark from $82.00 to $55.00 in a research report released on Thursday, BenzingaRatingsTable reports. Benchmark currently has a buy rating on the medical research company’s stock. BEAT has been the topic of several other reports. BidaskClub downgraded BioTelemetry from a buy rating to a hold rating in […]
  • 03/23/2020

BioTelemetry Inc (NASDAQ:BEAT) Expected to Post Earnings of $0.44 Per Share

  • Analysts forecast that BioTelemetry Inc (NASDAQ:BEAT) will post $0.44 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for BioTelemetry’s earnings, with estimates ranging from $0.41 to $0.46. BioTelemetry posted earnings per share of $0.42 during the same quarter last year, which suggests a positive year-over-year growth rate […]
  • 03/22/2020

Brokerages Expect BioTelemetry Inc (NASDAQ:BEAT) Will Announce Quarterly Sales of $114.42 Million

  • Brokerages expect that BioTelemetry Inc (NASDAQ:BEAT) will announce $114.42 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for BioTelemetry’s earnings. The highest sales estimate is $114.74 million and the lowest is $114.11 million. BioTelemetry posted sales of $103.98 million in the same quarter last year, which would indicate […]
  • 03/21/2020

How Does BioTelemetry’s (NASDAQ:BEAT) P/E Compare To Its Industry, After The Share Price Drop?

  • To the annoyance of some shareholders, BioTelemetry (NASDAQ:BEAT) shares are down a considerable 41% in the last...
  • 03/20/2020

Envestnet Asset Management Inc. Raises Stake in BioTelemetry Inc (NASDAQ:BEAT)

  • Envestnet Asset Management Inc. boosted its position in BioTelemetry Inc (NASDAQ:BEAT) by 21.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,482 shares of the medical research company’s stock after buying an additional 7,231 shares during the period. Envestnet Asset Management […]
  • 03/20/2020

BioTelemetry Inc (NASDAQ:BEAT) Shares Purchased by Bank of Montreal Can

  • Bank of Montreal Can lifted its position in BioTelemetry Inc (NASDAQ:BEAT) by 58.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,433 shares of the medical research company’s stock after purchasing an additional 2,745 shares during the quarter. Bank of […]
  • 03/20/2020

Ancora Advisors LLC Boosts Stake in BioTelemetry Inc (NASDAQ:BEAT)

  • Ancora Advisors LLC grew its stake in shares of BioTelemetry Inc (NASDAQ:BEAT) by 7.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 136,323 shares of the medical research company’s stock after buying an additional 10,000 shares during the quarter. Ancora Advisors LLC […]
  • 03/20/2020

BioTelemetry (NASDAQ:BEAT) Rating Lowered to Sell at BidaskClub

  • BioTelemetry (NASDAQ:BEAT) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Friday, BidAskClub reports. Other equities analysts also recently issued reports about the company. SunTrust Banks started coverage on BioTelemetry in a research note on Tuesday, January 7th. They issued a “buy” […]
  • 03/20/2020

Benchmark Maintains Buy on BioTelemetry, Lowers Price Target to $55

  • 03/19/2020

We Think BioTelemetry (NASDAQ:BEAT) Can Stay On Top Of Its Debt

  • Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
  • 03/19/2020

The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

  • Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
  • 03/19/2020

Great West Life Assurance Co. Can Makes New $1.87 Million Investment in BioTelemetry Inc (NASDAQ:BEAT)

  • Great West Life Assurance Co. Can bought a new position in BioTelemetry Inc (NASDAQ:BEAT) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 40,817 shares of the medical research company’s stock, valued at approximately $1,873,000. Great West Life Assurance Co. Can owned about 0.12% […]
  • 03/19/2020

The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

  • Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...
  • 03/19/2020

The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

  • Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
  • 03/18/2020

ArrowMark Colorado Holdings LLC Purchases 277,151 Shares of BioTelemetry Inc (NASDAQ:BEAT)

  • ArrowMark Colorado Holdings LLC lifted its position in BioTelemetry Inc (NASDAQ:BEAT) by 8.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,447,563 shares of the medical research company’s stock after buying an additional 277,151 shares during the quarter. BioTelemetry comprises approximately […]
  • 03/18/2020

The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

  • Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
  • 03/18/2020

BioTelemetry Inc (NASDAQ:BEAT) Short Interest Update

  • BioTelemetry Inc (NASDAQ:BEAT) was the recipient of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 2,510,000 shares, a decrease of 6.7% from the February 13th total of 2,690,000 shares. Approximately 7.6% of the company’s stock are sold short. Based on an average trading […]
  • 03/16/2020

Nioh 2 Guide: How to Interact with Purple Kodamas and How to Beat Mezuki

  • Welcome back to 1550s Japan!
  • 03/13/2020

How Does BioTelemetry's (NASDAQ:BEAT) P/E Compare To Its Industry, After The Share Price Drop?

  • To the annoyance of some shareholders, BioTelemetry (NASDAQ:BEAT) shares are down a considerable 35% in the last...
  • 03/13/2020

The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

  • Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...
  • 03/13/2020

Stocks That Hit 52-Week Lows On Thursday

  • 03/12/2020

The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

  • Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacted to its fourth-quarter results) * Centogene NV (NASDAQ: CNTG) * Tiziana Life Sciences PLC (NASDAQ
  • 03/12/2020

Cardiovascular Disease Monitoring and Diagnostic Devices Market Analysis 2020 - Worldwide Market Forecast to Grow by US$1.2 Billion

  • Dublin, March 12, 2020 -- The "Cardiovascular Disease Monitoring and Diagnostic Devices - Market Analysis, Trends, and Forecasts" report has been added to.
  • 03/12/2020

The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

  • Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...
  • 03/12/2020

Edited Transcript of BEAT earnings conference call or presentation 26-Feb-20 10:00pm GMT

  • Q4 2019 BioTelemetry Inc Earnings Call
  • 03/11/2020

The Global Holter Monitor Market is expected to grow by USD 176.83 mn during 2020-2024, progressing at a CAGR of 6% during the forecast period

  • New York, March 10, 2020 -- Reportlinker.com announces the release of the report "Global Holter Monitor Market 2020-2024" -.
  • 03/10/2020

Air Headphones? Apple's Leaked Images of Newest Over-the-Ear Headphones That'll Beat Beats or AirPods!

  • Coming in fall 2020
  • 03/10/2020

Charles Schwab Investment Management Inc. Buys 7,457 Shares of BioTelemetry Inc (NASDAQ:BEAT)

  • Charles Schwab Investment Management Inc. lifted its stake in BioTelemetry Inc (NASDAQ:BEAT) by 3.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 209,123 shares of the medical research company’s stock after purchasing an additional 7,457 shares during the period. […]
  • 03/09/2020

What Does BioTelemetry, Inc.’s (NASDAQ:BEAT) P/E Ratio Tell You?

  • The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll show how you can use...
  • 03/06/2020

Netflix VS HBO: Can HBO's Upcoming Video Game Turned Show "The Last of Us" Beat "The Witcher?"

  • After the hype of Game of Thrones, fans were still looking for more of a similar genre, which was when Netflix decided to release The Witcher, gaining amazing success! Can HBO do the same with The Last of Us?
  • 03/06/2020

Edited Transcript of BEAT earnings conference call or presentation 26-Feb-20 10:00pm GMT

  • Q4 2019 BioTelemetry Inc Earnings Call
  • 03/05/2020

The Global Wearable Medical Devices MARKET is expected to grow by USD 10.24 bn during 2020-2024, progressing at a CAGR of 10% during the forecast period

  • New York, March 03, 2020 -- Reportlinker.com announces the release of the report "Global Wearable Medical Devices Market 2020-2024" -.
  • 03/04/2020

Global Cardiovascular Disease Monitoring and Diagnostic Devices Industry

  • New York, March 03, 2020 -- Reportlinker.com announces the release of the report "Global Cardiovascular Disease Monitoring and Diagnostic Devices Industry" -.
  • 03/03/2020

Global Cardiovascular Disease Monitoring and Diagnostic Devices Industry

  • Cardiovascular Disease Monitoring and Diagnostic Devices market worldwide is projected to grow by US$1.2 Billion, driven by a compounded growth of 7%. ECG Systems, one of the segments analyzed and sized in this study, displays the potential to grow at over 7.1%. The shifting dynamics supporting this
  • 03/03/2020

Cardiac Rehabilitation Market To Reach USD 2.29 Billion By 2026 | Reports and Data

  • According to the current analysis of Reports and Data, the cardiac rehabilitation market was valued at USD 1.37 billion in 2018 and is expected to reach USD 2.29 billion by the year 2026, at a CAGR of 6.6 %. Cardiac rehabilitation is a healthcare program that guides people who have survived a heart
  • 03/02/2020

BioTelemetry (NASDAQ:BEAT) Rating Lowered to Hold at BidaskClub

  • BioTelemetry (NASDAQ:BEAT) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Saturday, BidAskClub reports. A number of other equities analysts have also recently weighed in on the stock. Sidoti reduced their price objective on shares of BioTelemetry from $81.00 to $75.00 and set a “buy” rating […]
  • 03/02/2020

Sidoti Cuts BioTelemetry (NASDAQ:BEAT) Price Target to $75.00

  • BioTelemetry (NASDAQ:BEAT) had its target price reduced by Sidoti from $81.00 to $75.00 in a research report report published on Thursday morning, BenzingaRatingsTable reports. Sidoti currently has a buy rating on the medical research company’s stock. BEAT has been the subject of several other research reports. SunTrust Banks initiated coverage on shares of BioTelemetry in […]
  • 03/02/2020

6,450 Shares in BioTelemetry Inc (NASDAQ:BEAT) Acquired by Banque Cantonale Vaudoise

  • Banque Cantonale Vaudoise acquired a new position in shares of BioTelemetry Inc (NASDAQ:BEAT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 6,450 shares of the medical research company’s stock, valued at approximately $299,000. Other institutional investors have also recently […]
  • 03/02/2020

Altshuler Shaham Ltd Has $246,000 Position in BioTelemetry Inc (NASDAQ:BEAT)

  • Altshuler Shaham Ltd raised its stake in BioTelemetry Inc (NASDAQ:BEAT) by 8.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 5,300 shares of the medical research company’s stock after acquiring an additional 400 shares during the period. Altshuler Shaham Ltd’s holdings in BioTelemetry were worth $246,000 at the end of the most recent […]
  • 03/02/2020

Short Interest in BioTelemetry Inc (NASDAQ:BEAT) Rises By 7.4%

  • BioTelemetry Inc (NASDAQ:BEAT) saw a large increase in short interest in the month of February. As of February 14th, there was short interest totalling 3,040,000 shares, an increase of 7.4% from the January 30th total of 2,830,000 shares. Based on an average daily volume of 236,100 shares, the days-to-cover ratio is presently 12.9 days. Approximately […]
  • 03/02/2020

BioTelemetry Inc (NASDAQ:BEAT) Expected to Earn FY2021 Earnings of $2.27 Per Share

  • BioTelemetry Inc (NASDAQ:BEAT) – Equities researchers at Dougherty & Co issued their FY2021 earnings per share estimates for shares of BioTelemetry in a note issued to investors on Thursday, February 27th. Dougherty & Co analyst G. Mannheimer anticipates that the medical research company will earn $2.27 per share for the year. Other equities research analysts […]
  • 03/02/2020

Pokemon Go: Tricks and Counter Tips on How to Beat Nidorino in Raid!

  • Raid bosses are usually tough, but there are specific weaknesses to every single one of them! Nidorino in Pokemon Go is no exemption to this list. Find out how to beat this raid boss easily!
  • 03/02/2020

Los Angeles Capital Management & Equity Research Inc. Cuts Stock Position in BioTelemetry Inc (NASDAQ:BEAT)

  • Los Angeles Capital Management & Equity Research Inc. cut its holdings in shares of BioTelemetry Inc (NASDAQ:BEAT) by 25.0% during the fourth quarter, Holdings Channel reports. The firm owned 5,663 shares of the medical research company’s stock after selling 1,890 shares during the quarter. Los Angeles Capital Management & Equity Research Inc.’s holdings in BioTelemetry […]
  • 03/01/2020

BioTelemetry (NASDAQ:BEAT) Lowered to "Sell" at Zacks Investment Research

  • Zacks Investment Research downgraded shares of BioTelemetry (NASDAQ:BEAT) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning, Zacks.com reports. According to Zacks, “BioTelemetry, Inc. provides ambulatory outpatient management solutions for monitoring clinical information regarding an individual’s health. It is focused on the diagnosis and monitoring of […]
  • 03/01/2020

BioTelemetry (NASDAQ:BEAT) Cut to C at TheStreet

  • TheStreet cut shares of BioTelemetry (NASDAQ:BEAT) from a b- rating to a c rating in a research report sent to investors on Wednesday morning, TheStreetRatingsTable reports. BEAT has been the subject of a number of other research reports. SunTrust Banks started coverage on BioTelemetry in a report on Tuesday, January 7th. They set a buy […]
  • 02/29/2020

BioTelemetry Inc Expected to Post Q1 2020 Earnings of $0.45 Per Share (NASDAQ:BEAT)

  • BioTelemetry Inc (NASDAQ:BEAT) – Research analysts at SunTrust Banks decreased their Q1 2020 earnings per share estimates for BioTelemetry in a report issued on Wednesday, February 26th. SunTrust Banks analyst K. Krum now anticipates that the medical research company will post earnings per share of $0.45 for the quarter, down from their previous forecast of […]
  • 02/29/2020

Insights into the Global Telemedicine Market to 2024 - Featuring Aerotel Medical Systems, Allscripts Healthcare Solutions & BioTelemetry Among Others - ResearchAndMarkets.com

  • The "Global Telemedicine Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • 02/28/2020

Dougherty & Co Weighs in on BioTelemetry Inc's Q1 2020 Earnings (NASDAQ:BEAT)

  • BioTelemetry Inc (NASDAQ:BEAT) – Stock analysts at Dougherty & Co issued their Q1 2020 earnings per share estimates for shares of BioTelemetry in a research report issued on Thursday, February 27th. Dougherty & Co analyst G. Mannheimer forecasts that the medical research company will earn $0.46 per share for the quarter. Dougherty & Co also […]
  • 02/28/2020

BioTelemetry (NASDAQ:BEAT) Trading Down 6.2% Following Analyst Downgrade

  • BioTelemetry Inc (NASDAQ:BEAT) was down 6.2% during trading on Thursday after Sidoti lowered their price target on the stock from $81.00 to $75.00. Sidoti currently has a buy rating on the stock. BioTelemetry traded as low as $40.00 and last traded at $45.01, approximately 878,763 shares were traded during mid-day trading. An increase of 243% […]
  • 02/28/2020

Sidoti & Co. Maintains Buy on BioTelemetry, Lowers Price Target to $75

  • 02/27/2020

Zacks: Brokerages Expect BioTelemetry Inc (NASDAQ:BEAT) Will Announce Quarterly Sales of $110.35 Million

  • Analysts expect BioTelemetry Inc (NASDAQ:BEAT) to report sales of $110.35 million for the current quarter, Zacks reports. Three analysts have made estimates for BioTelemetry’s earnings, with the highest sales estimate coming in at $111.44 million and the lowest estimate coming in at $108.90 million. BioTelemetry posted sales of $103.60 million in the same quarter last […]
  • 02/27/2020

FY2020 EPS Estimates for BioTelemetry Inc (NASDAQ:BEAT) Decreased by Analyst

  • BioTelemetry Inc (NASDAQ:BEAT) – Research analysts at Dougherty & Co dropped their FY2020 earnings per share estimates for BioTelemetry in a report issued on Monday, February 24th. Dougherty & Co analyst G. Mannheimer now anticipates that the medical research company will post earnings per share of $2.15 for the year, down from their prior estimate […]
  • 02/27/2020

Pokemon Sword and Shield Raid Update: Tips on How to Find and Beat Mewtwo on Pokemon Day

  • ...and steps on how to beat Mewtwo!
  • 02/27/2020

BioTelemetry, Inc. (BEAT) CEO Joseph Capper on Q4 2019 Results - Earnings Call Transcript

  • BioTelemetry, Inc. (NASDAQ:BEAT) Q4 2019 Earnings Conference Call February 26, 2020, 05:00 PM ET Company Participants Joseph Capper - President and CEO Heather
  • 02/27/2020

BioTelemetry Inc (BEAT) Q4 2019 Earnings Call Transcript

  • BEAT earnings call for the period ending December 31, 2019.
  • 02/27/2020

BioTelemetry (BEAT) Q4 Earnings Meet Estimates

  • BioTelemetry (BEAT) delivered earnings and revenue surprises of 0.00% and 1.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
  • 02/26/2020

BioTelemetry (BEAT) Q4 Earnings Meet Estimates

  • BioTelemetry (BEAT) delivered earnings and revenue surprises of 0.00% and 1.53%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
  • 02/26/2020

BRIEF-BioTelemetry Posts Quarterly Adjusted Earnings Per Share Of 48 Cents

  • BioTelemetry Inc:
  • 02/26/2020

BioTelemetry: 4Q Earnings Snapshot

  • MALVERN, Pa. (AP) _ BioTelemetry Inc. (BEAT) on Wednesday reported fourth-quarter net income of $1.6 million. The Malvern, Pennsylvania-based company said it had net income of 4 cents per share. Earnings, adjusted for one-time gains and costs, were 4
  • 02/26/2020
Unlock
BEAT Ratings Summary
BEAT Quant Ranking